# OnCo record nct06443671 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06443671/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06443671", "NCT06443671" ;
  schema:name "Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for Mid-high pMMR/MSS Locally Advanced Rectal Cancer"@en ;
  schema:alternateName "PKUCH-R09"@en ;
  schema:description "A phase 2/3 trial of cAPOX (capecitabine, oxaliplatin), fruquintinib and tislelizumab in colorectal cancer, run by Peking University Cancer Hospital & Institute, not yet recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06443671/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06443671> ;
  onco:status "planned" ;
  onco:tag "ctgov-ingest", "colorectal-deep-dive" ;
  onco:phase "2/3" ;
  onco:cancers <https://onco.cc/cancers/rectal-cancer/> ;
  onco:technologies <https://onco.cc/technologies/antiangiogenic/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/platinum/> ;
  onco:drugs <https://onco.cc/drugs/capox/>, <https://onco.cc/drugs/fruquintinib/>, <https://onco.cc/drugs/tislelizumab/> .